Section N2. Research Team and Research Capabilities, Center Organization and Infrastructure (Administrative Core) 1) Research Team Outline the major strength of the team and specific senior investigators In the context of the proposed area of focus; Successful application of nanotechnology to cancer requires an interactive and diverse team with innovative and creative solutions. The innovation and goals proposed In our CCNE are challenging but mirror the strength of our researchers and partnerships, especially since our focus is to transition these nanotechnologies to cancer disease management. Our team reflects that focus and combines expertise in the basic science of nanotechnology working In concert with translational research oriented clinicians who can help both the broad and the specific research agenda to maximize a direct impact on patient care. In addition, we have successfully combined researchers from four schools on the UNC campus: the Schools of Medicine, Arts and Sciences, Pharmacy and Public Health. This diversity of expertise and interests will help to ensure the success of our program. Our research team is led by Co-Principal Investigators, Joseph M. DeSimone, Ph.D. and Joel Tepper, M.D., who bring extensive experience in scientific leadership across the continuum from basic science to clinical development. We have emphasized this bridging of basic and clinical sciences throughout our proposal to demonstrate our understanding of and commitment to the challenge of bringing nanotechnology applications to cancer patients. Our projects feature nanotechnologies that are singular to the University of North Carolina at Chapel Hill, build on innovative ideas that have originated within our group, and reflect the highest caliber of scientists who discovered and developed them. We are confident that our mix of ideas, people and technologies is ideally suited to deliver on the promise of Nanomedicine. The University of North Carolina at Chapel Hill prides itself on being a leading institute in both medical and physical sciences and also providing and facilitating an environment of inter-disciplinary interactions. The cancer research community at UNC is anchored by the UNC Lineberger Comprehensive Cancer Center with a 35-year history. It is further strengthened by the presence of two NCI Specialized Programs of Research Excellence (SPOREs) in Breast and Gl cancer. The physical sciences aspects of our center are supported by the newly formed Institute for Nanomedicine, the Institute for Advanced Materials, Nanoscience and Technology (lAM) and the Chapel Hill Analytical and Nanofabrication Laboratory (CHANL). The Center for Nanotechnology in Drug Delivery and the Translational Oncology and Nanoparticle Drug Development Initiative (TONDDI) Lab at the Eshelman School of Pharmacy help transition nanomaterial discoveries toward the clinic. The $50 million/year University Cancer Research Fund (UCRF) and UNC's Clinical and Translational Science Award (CTSA) further enhance the entrepreneurial and translational aspects of our efforts of bringing relief to cancer patients. Our Center leadership will have all these resources to support a cohesive, stimulating, and effective CCNE. Our team and resources are discussed in more detail in the following sections.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
5U54CA151652-05
Application #
8711363
Study Section
Special Emphasis Panel (ZCA1-GRB-S)
Project Start
Project End
Budget Start
2014-08-01
Budget End
2015-07-31
Support Year
5
Fiscal Year
2014
Total Cost
$158,145
Indirect Cost
Name
University of North Carolina Chapel Hill
Department
Type
DUNS #
608195277
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Lucas, Andrew T; O'Neal, Sara K; Santos, Charlene M et al. (2016) A sensitive high performance liquid chromatography assay for the quantification of doxorubicin associated with DNA in tumor and tissues. J Pharm Biomed Anal 119:122-9
Kai, Marc P; Brighton, Hailey E; Fromen, Catherine A et al. (2016) Tumor Presence Induces Global Immune Changes and Enhances Nanoparticle Clearance. ACS Nano 10:861-70
Roode, Luke E; Brighton, Hailey; Bo, Tao et al. (2016) Subtumoral analysis of PRINT nanoparticle distribution reveals targeting variation based on cellular and particle properties. Nanomedicine 12:1053-62
Miao, Lei; Liu, Qi; Lin, C Michael et al. (2016) Targeting Tumor-associated Fibroblasts for Therapeutic Delivery in Desmoplastic Tumors. Cancer Res :
Li, Chengwen; Wu, Shuqing; Albright, Blake et al. (2016) Development of Patient-specific AAV Vectors After Neutralizing Antibody Selection for Enhanced Muscle Gene Transfer. Mol Ther 24:53-65
DeSimone, Joseph M; Mecham, Sue J; Farrell, Crista L (2016) Organic Polymer Chemistry in the Context of Novel Processes. ACS Cent Sci 2:588-597
Lecaros, Rumwald Leo G; Huang, Leaf; Lee, Tsai-Chia et al. (2016) Nanoparticle Delivered VEGF-A siRNA Enhances Photodynamic Therapy for Head and Neck Cancer Treatment. Mol Ther 24:106-16
Lu, Yao; Miao, Lei; Wang, Yuhua et al. (2016) Curcumin Micelles Remodel Tumor Microenvironment and Enhance Vaccine Activity in an Advanced Melanoma Model. Mol Ther 24:364-74
Sambade, Maria; Deal, Allison; Schorzman, Allison et al. (2016) Efficacy and pharmacokinetics of a modified acid-labile docetaxel-PRINT(®) nanoparticle formulation against non-small-cell lung cancer brain metastases. Nanomedicine (Lond) 11:1947-55
Rose, Tracy L; Deal, Allison M; Ladoire, Sylvain et al. (2016) Patterns of Bladder Preservation Therapy Utilization for Muscle-Invasive Bladder Cancer. Bladder Cancer 2:405-413

Showing the most recent 10 out of 158 publications